Usefulness of HeberFERON® in patients with basal cell carcinoma

• Váldodahkkit: Natacha López Pupo (Dahkki), Yarien Manganelly Fonseca (Dahkki), María Elena Tablada Robinet (Dahkki), Ana Lucía Jacas Portuondo (Dahkki), Yaimaris Girón Maturell (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Centro Provincial de Información de Ciencias Médicas, 2021-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction: The basal cell carcinoma is the most frequent epithelial neoplasm, because it constitutes 60-80 % of all the cutaneous cancers.  Objective: To determine the answer to HeberFERON® in patients with basal cell carcinoma.  Methods:  An observational, descriptive and longitudinal study of 9...